Verrica Pharmaceuticals Inc.
VRCAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 27, 2026 | Lake Street | $9.00(+80%) | $5.00 | TheFly | |
| Dec 18, 2025 | Loop Capital Markets | Kemp Dolliver | $17.00(+111%) | $8.05 | StreetInsider |
| May 14, 2024 | Jefferies | Glen Santangelo | $12.00(+6%) | $11.28 | StreetInsider |
| May 14, 2024 | H.C. Wainwright | Oren Livnat | $14.00(+46%) | $9.56 | StreetInsider |
| Jul 25, 2023 | Needham | Serge Belanger | $10.00(+88%) | $5.32 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Brookline Capital | upgrade | Hold →Buy | Dec 18, 2025 |
| Needham | maintain | Hold | May 14, 2025 |
| Needham | maintain | Hold | Apr 9, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Apr 8, 2025 |
| Needham | maintain | Hold | Mar 12, 2025 |
| Needham | maintain | Hold | Dec 20, 2024 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Nov 6, 2024 |
| RBC Capital | downgrade | Outperform →Sector Perform | Nov 5, 2024 |
| TD Cowen | maintain | Buy | Oct 21, 2024 |
| RBC Capital | maintain | Outperform | Oct 4, 2024 |
| Needham | downgrade | Buy →Hold | Oct 3, 2024 |
| Brookline Capital | downgrade | Buy →Hold | Oct 2, 2024 |
| Needham | maintain | Buy | Aug 15, 2024 |
| RBC Capital | maintain | Outperform | Aug 15, 2024 |
| Needham | maintain | Buy | May 16, 2024 |
| Needham | maintain | Buy | May 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| Needham | maintain | Buy | Apr 10, 2024 |
| Needham | maintain | Buy | Mar 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 1, 2024 |
| Jefferies | maintain | Buy | Dec 15, 2023 |
| Needham | maintain | Buy | Nov 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 12, 2023 |
| Needham | maintain | Buy | Aug 23, 2023 |
| Needham | maintain | Buy | Aug 10, 2023 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.50| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.62 | $-0.39 | $5.9M | $5.7M |
| May 12, 2026 | $-0.41 | $-0.59 | $5.0M | $4.5M |
| Mar 11, 2026 | $-0.51 | $-0.43 | $5.1M | $4.5M |
| Nov 14, 2025 | $-0.03 | $-1.14 | $14.3M | $9.8M |
| Aug 12, 2025 | $0.02 | $-0.70 | $12.7M | $4.3M |
| May 13, 2025 | $-1.00 | $-1.23 | $3.4M | $2.5M |
| Mar 11, 2025 | $-2.40 | $-0.32 | $344.0K | $1.0M |
| Nov 4, 2024 | $-4.90 | $-3.70 | -$1.8M | $5.3M |
News
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m.
– Company's achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and advancement of the Company's global Phase 3 common warts program through topline data readouts, the first of which is expected in Q1'27 – WEST CHESTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company d…
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA - Get Free Report) has been given an average recommendation of "Hold" by the five ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C.
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological disea…